

RESEARCH ARTICLE

MEDICAL PHYSICS

Deep learning-based synthetic-CT-free photon dose calculation in MR-guided radiotherapy: A proof-of-concept study

Fan Xiao¹ | Domagoj Radonic¹ | Niklas Wahl^{2,3} | Nikolaos Delopoulos¹ |
 Adrian Thummerer¹ | Stefanie Corradini¹ | Claus Belka^{1,4,5} | George Dedes⁶ |
 Christopher Kurz¹ | Guillaume Landry^{1,5}

¹Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany

²Department of Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany

³National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany

⁴German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU University Hospital, Munich, Germany

⁵Bavarian Cancer Research Center (BZKF), Munich, Germany

⁶Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Munich, Germany

Correspondence

Guillaume Landry, Department of Radiation Oncology, LMU University Hospital, LMU Munich, 81377 Munich, Germany.
 Email: guillaume.landry@med.uni-muenchen.de

Funding information

China Scholarship Council, Grant/Award Number: 202308440107; Deutsche Forschungsgemeinschaft, Grant/Award Number: 469106425

Abstract

Background: In magnetic resonance imaging (MRI)-guided online adaptive radiotherapy, MRI lacks tissue attenuation information necessary for accurate dose calculations. Although deep learning (DL)-based synthetic computed tomography (CT) generation models have been developed to obtain CT density information from MRI, they usually do not meet the requirement of real-time plan adaptation.

Purpose: We propose a DL-based photon dose calculation method directly on 0.35 T MRI to skip synthetic CT generation and show its feasibility for prostate patient cases.

Methods: The 0.35 T planning MRI and deformed planning CT (registered to the planning MRI) of 34 prostate cancer patients treated with a 0.35 T magnetic resonance-linear accelerator (MR-Linac) were collected. The air cavities (ACs) in the abdominopelvic area of the deformed CT images were corrected based on manual AC contouring on the MRI. Monte Carlo (MC) dose simulations under a 0.35 T magnetic field were performed on the corrected CT images. All photon beams were simulated using a uniform field size of 1 cm × 1 cm. 10 800 beams were simulated with 5×10^6 initial photons for training (20 patients) and 2160 beams with 5×10^7 photons for validation (4 patients). For testing, 1080 beams shooting through the planning target volume (PTV) in 10 patients and five optimized nine-field intensity-modulated plans were simulated with 5×10^7 photons. 3D MRI cuboids covering the photon beams were input into a Unet model to predict AC segmentation, and 3D MRI and predicted AC cuboids were input into a long short-term memory (LSTM) model for beam's eye view (BEV) processing to predict dose. The gamma passing rate γ_{pr} (2%/2mm, $D > 10\%D_{max}$), beam dose profiles of single beams and dose volume histogram (DVH) of intensity-modulated plans were evaluated.

Results: The test results for all photon beams from the proposed models demonstrated a mean γ_{pr} above 99.50%. The five treatment plans recalculated by the DL model each achieved γ_{pr} values exceeding 99.80%. Additionally, the model's inference time was approximately 12 ms per photon beam.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Conclusions: The proposed method showed that DL-based dose calculation directly on MRI is feasible for prostate cases, which has the potential to simplify the procedure for MRI-only workflows and can be beneficial for real-time plan adaptation.

KEYWORDS

deep learning, dose calculation, LSTM, MRI, online MR-guided photon therapy

1 | INTRODUCTION

Magnetic resonance imaging (MRI) is becoming widely used in radiotherapy because of its high soft tissue contrast to visualize target volumes and its image acquisition process based on nonionizing radiation.¹ Magnetic resonance-linear accelerators (MR-Linacs)^{2,3} combine a linac with an MR scanner, making MRI-guided online adaptive radiotherapy feasible.^{4,5} The daily treatment plan can be adapted to manage inter-fractional variations, and intra-fractional beam gating based on real-time 2D cine MRI sequences⁶ can account for the target/tumor motion during treatment.^{7,8} Ideally, the ultimate approach would be real-time adaptation, which would rely on real-time 3D MRI^{9,10} to recalculate the delivered dose based on the latest geometry, and accumulate dose to re-optimize the remaining dose within this fraction.^{11,12}

For plan re-optimization, MRI cannot be used directly as it lacks electron density information required for accurate dose calculations. A variety of synthetic computed tomography (CT) generation methods from MRI have been developed¹³ and recently deep learning (DL)-based methods showed promising results. Based on the SynthRAD2023 challenge report,^{14,15} different DL models are proposed to generate 2D/3D synthetic CT from MRI and top-performing teams achieved an average 99.0% gamma passing rates (2%/2 mm, 10% dose threshold of the prescribed dose) in photon treatment plans. However, the average inference time per patient for DL models was 5.2 ± 2.8 min.¹⁵ Although DL-based synthetic CT studies published in 2025^{16,17} have reported average processing times of under 2 min per patient, these times remain acceptable for daily plan adaptation, but do not meet the requirement of real-time adaptation.

On the other hand, fast dose calculations are critical for online plan re-optimization and ultimately for accounting for intra-fractional motion. For MR-Linacs, the effect of the magnetic field on dose can be considered by Monte-Carlo (MC) simulation.¹⁸ Although traditional MC methods¹⁹ are highly time-consuming, graphics processing unit (GPU)-based approaches^{20,21} have accelerated MC photon dose calculation to a few or tens of seconds. Meanwhile, DL methods have achieved sub-second^{22,23} or nearly 1s^{24,25} photon dose

calculation speeds with promising accuracy, offering the possibility for real-time plan adaptation.

Given that DL methods can accurately generate synthetic CT from MRI and perform dose calculations based on CT with high precision (to the best of our knowledge, all DL dose calculation methods are CT-based), it would be highly valuable to explore the potential of DL methods for direct dose calculation on MRI, as also discussed in some studies.^{26,27} By bypassing the time-consuming synthetic CT generation process, DL dose calculation on MRI has the potential to support real-time intra-fractional plan adaptation based on 3D time-resolved MRI from MR-Linacs.²⁸

In this work, building upon the previous long short-term memory (LSTM)-based proton dose calculation studies addressing dose calculation in beam's eye view (BEV),^{29,30} we explore the use of Unet-LSTM combined networks to directly build the mapping between the MRI and the photon beam dose simulated on the corresponding deformed CT. For this proof-of-concept experiment, we train, validate, and test the network on prostate cancer patient datasets, and all photon beams were simulated with a uniform small-sized field.

2 | MATERIALS AND METHODS

2.1 | Patient data

The patient dataset consists of imaging data from 34 prostate cancer patients treated with the 0.35 T MR-Linac (MRIdian, ViewRay, USA)³ at the Department of Radiation Oncology, LMU University Hospital. For each patient case, the planning MRIs were acquired at the 0.35 T MR-Linac using a balanced steady state free-precession (bSSFP) sequence (yielding a T2/T1-weighted contrast).³¹ The planning CT images obtained from a single CT scanner (Aquilion LB, Canon Medical Systems, NL) were deformably registered to planning MRI in the ViewRay treatment planning system (TPS),³² using an intensity-based algorithm. For each pair of planning MRI and deformed CT, the resulting registration was visually verified by physicians during the online adaptive workflow.³³ The voxel size of both planning MRI and deformed planning CT was $1.5 \times 1.5 \times 1.5$ mm³. All patients were anonymized and had no artificial implants.




FIGURE 1 AC correction in the transverse plane of a prostate case: (a) deformed CT with filled AC (blue area), (b) AC contours on MRI (red area indicates the AC contour), (c) corrected CT. AC, air cavity; CT, computed tomography; MRI, magnetic resonance imaging.

2.2 | Air cavity (AC) correction

Although electron density transfer based on deformable image registration (DIR) can achieve high accuracy, it still has limitations when handling the addition or removal of new tissue compartments, especially in cases of air/gas volume changes within the abdominopelvic region.³⁴ To take AC changes into account for accurate comparison of dose calculations on deformed CTs and MRIs, we applied AC correction to the deformed CT based on the corresponding MRI for each patient. As shown in Figure 1, the following three steps were performed: (1) Extract AC masks in deformed CT using Hounsfield Unit (HU) thresholding (CT values < -300 HU). For each unconnected component of the AC mask, calculate the median values of neighbor voxels and fill the corresponding AC region with these median values to obtain the filled CT. (2) Manually delineate AC contours on the MRI using a research version of a commercial TPS (RayStation, RaySearch Laboratories, Stockholm, Sweden), as long as the ACs were located within the peri-prostatic region, regardless of their volume. Additionally, TotalSegmentator³⁵ was applied to MRI to generate gas-containing organ masks (colon, bowel, duodenum, rectum), enabling rough localization of gas-containing organs to facilitate manual AC contouring. (3) Insert AC contours from MRI to filled CT and assign an AC value of -700 HU, as referenced in ref. [36]. We used the corrected CT for MC simulation to generate dose distributions for training and evaluating the model.

2.3 | MC simulation

In this work, MC dose distributions were simulated using Geant4 v11.00-patch-03 with the predefined QGSP_BIC_HP_EMZ physics list. CT numbers of corrected CTs were converted to mass density and elemental composition using a scanner-specific calibration curve established in a previous study.³⁷ The photon energy spectrum we used in our Geant4 simulations was extracted from the ELEKTA_PRECISE_6MV phase space files provided and validated by the International Atomic Energy Agency (IAEA).³⁸ A uniform 0.35 T magnetic field was simulated in Geant4, aligned parallel to the superior-inferior patient direction and confined within

a cylindrical region with a 50 cm diameter.³ The dose distribution was scored on the same voxel geometry as the corrected CT.

For this proof-of-concept study, all photon beams were simulated parallel to the transverse plane with a uniform square field size of $1 \times 1 \text{ cm}^2$, based on a plane source with the extracted photon energy spectrum. The source-to-axis distance was set to 100 cm and gantry angles of photon beams were multiples of 10° . Twenty patients were randomly selected for training, 4 patients for validation and 10 patients for testing. For each training and validation patient, the isocenter was shifted to three positions along the anterior–posterior (AP) direction (0 cm, +3 cm, -3 cm) and five positions along the superior–inferior (SI) direction (-4 cm, -2 cm, 0 cm, +2 cm, +4 cm). For each isocenter position, 36 evenly spaced gantry angles (every 10° from 0° to 350°) were simulated, resulting in a total of $36 \times 3 \times 5 = 540$ beams per patient. For test patients, three random positions of iso center within or near the edge of the planning target volume (PTV) in superior-inferior direction were selected, yielding 36×3 beams simulated per patient. In total, 10800 beams were simulated for 20 training patients, 2160 beams simulated for 4 validation patients, and 1080 beams through the PTV simulated for 10 test patients. Due to simulation time limitations (with a mean runtime of approximately 20 h for 5×10^7 histories on a single core of an Intel Xeon Gold 6354 3.00 GHz CPU), each training beam was simulated with 5×10^6 histories (with an average statistical uncertainty of approximately 4.5% in the $D > 10\% D_{\max}$ region, and a runtime of 2 h), while each validation and test beam was simulated with 5×10^7 histories (with an average statistical uncertainty of less than 1.5% in the $D > 10\% D_{\max}$ region, and a runtime of 20 h).

In addition to the single beam evaluation, five patients were selected from the 10 test patients for evaluation of full treatment plans. Four cases were randomly selected (plans 1, 3, 4 and 5) and one case was selected with an AC near the PTV on the MRI (plan 2). Five nine-field intensity-modulated plans with gantry angles of 0° , 40° , 80° , 120° , 160° , 200° , 240° , 280° , and 320° were generated and optimized with pyRadPlan v0.2.8,³⁹ an open-source Python treatment planning toolkit based on matRad.^{40,41} Specifically, each field comprised 81 parallel beams with a uniform square field size of $1 \times 1 \text{ cm}^2$, pre-calculated using 5×10^7 histories. The corrected CTs

and PTV masks, along with the MC beam doses, were imported into pyRadPlan, where treatment plans were then optimized by weighting the individual $1 \times 1 \text{ cm}^2$ beams using a quadratic difference objective for the PTV trading against a quadratic overdose objective for the normal tissue. The prescribed dose was 74 Gy delivered in 37 fractions, which is a standard and commonly used conventional fractionation regimen for prostate cancer at regular linacs. Please keep in mind that the fractionation is not relevant to the relative dose accuracy evaluations done in this work. MC treatment plans were normalized such that $D_{95\%}$ of the PTV received at least 95% of the prescribed dose (i.e., 70.4 Gy in this study). Then, the total MC and predicted doses of the five nine-field plans, obtained using identical optimized weights and the same scaling factor applied for normalizing the MC plans, were compared (see section 2.6).

2.4 | Pre-processing

After the MC simulation, all values of the 3D photon beam dose and 3D MRI maps outside the patient's body were set to 0 based on the body contour from the 3D MRI. The intensity values of each 3D MRI volume were clipped at the 99.5th percentile to account for potential high-intensity MRI artifacts. Patient-specific maximum normalization was applied to the 3D MRI volumes, while global maximum normalization, using the maximum beam dose value from training beams, was applied to the 3D beam dose volumes of the training, validation, and testing datasets. Next, BEV cuboid extraction operations based on the beam direction and source position were applied on the normalized 3D beam dose and MRI volumes, as well as the 3D AC contour volumes. 3D cuboids of MRI, AC and dose maps were cropped from the patient's surface and resampled. The dimensions of all 3D cuboids ($z \times y \times x$) were set to $200 \times 32 \times 32$, corresponding to the penetration depth z and the xy -plane perpendicular to it (the x -axis being parallel to the superior-inferior direction), with a resolution of $2 \times 2 \times 2 \text{ mm}^3$. Besides, to consider the lateral dose shift and electron return effect (ERE) due to the magnetic field, the cuboid center was shifted 1 cm in the y -axis with respect to the beam's center. To facilitate comparison with a CT-based dose calculation model, the corresponding corrected CT cuboids using the same global normalization and BEV extraction operations were also collected.

2.5 | Model architecture

Four models, as shown in Figure 2 were proposed: Model 0, serving as the baseline, was a CT-based dose calculation model that took CT cuboids as inputs (with globally normalized HU values) and generated dose

cuboids as outputs. The same LSTM model architecture in a previous study³⁰ was used (no energy embedding layer), consisting of a one-layer LSTM network and a two-layer fully-connected network, which converts a sequence of CT slices to a sequence of dose slices.

Unlike CT, which features distinguishable ACs with low-intensity values, MRI presents numerous low-signal areas that resemble ACs. This leads the LSTM Model to overlook the dose effects associated with ACs when relying solely on the MRI cuboid. To address this limitation, we introduce Model 1, which uses both MRI and manually contoured AC cuboids as inputs of the LSTM model to increase the model's focus to the AC area. It converts a sequence of MRI and AC slices to a sequence of dose slices (training framework shown in Figure 3, similar to a previous study⁴²).

The manual AC contouring as an input for dose calculation is not realistic for online workflows. Thus, inspired by an AC segmentation study on MRI,⁴³ we first trained an AC segmentation Unet model which can predict the 3D AC cuboid from the 3D MRI cuboid. Then, based on the trained LSTM model from Model 1 and the trained Unet, the dose cuboid can be inferred by inputting the MRI cuboid into the two models with frozen weights. As shown in Figure 2c, we refer to the models (LSTM and Unet) trained separately but used for joint inference as Model 2.

For Model 3, instead of training the Unet and LSTM models separately, we trained them jointly using a combined loss, which is the sum of the AC segmentation loss and the dose prediction loss. The models are also used jointly for inference, as shown in Figure 2d.

For the network architecture, the LSTM models used in the above four models are the same, and the Unet models used in Model 2 and Model 3 are the same. The LSTM model features one layer with a hidden state of size 1000, followed by two fully-connected layers, each containing 100 neurons and using ReLU activation functions. The Unet model is a simple 3D Unet with a three-level encoder-decoder structure. The encoder comprises two convolutional blocks, each consisting of two convolutional layers (kernel size = 3), followed by batch normalization and ReLU activation. The first block uses 32 filters, while the second employs 64 filters, with both blocks subsequently followed by max pooling for spatial downsampling. A bottleneck convolutional block with 128 filters further extracts high-level features. The decoder path mirrors the encoder, using transposed convolutional upsampling layers (kernel size = 2) and skip connections to restore spatial details, with filter numbers decreasing from 128 to 64 and then 32. A final $1 \times 1 \times 1$ convolution with a sigmoid activation generates the AC cuboid output, which is continuous between 0 and 1 and serves as a probability map.

For the model training, all LSTM models employed a mean squared error (MSE)-based loss. Specifically, Model 0 utilized a standard MSE loss, while the loss




FIGURE 2 Overview of the four proposed models: (a) Model 0: the LSTM model converting CT to dose, (b) Model 1: the LSTM model converting MRI and manual AC to dose, (c) Model 2: the Unet model converting MRI to predicted AC, and the LSTM model from Model 1 converting MRI and predicted AC to dose, (d) Model 3: jointly trained Unet and LSTM models. Training was conducted using MSE loss for dose prediction and BCE loss for AC segmentation. Models with frozen weights in (c) refer to pre-trained models for inference. AC, air cavities; BCE, binary cross-entropy; CT, computed tomography; LSTM, long short-term memory; MRI, magnetic resonance imaging; MSE, mean squared error.




FIGURE 3 Training framework of Model 1: (a, left) The 3D input MRI and AC cuboid and ground truth dose cuboid after BEV resampling. (a, right) The slices of MRI and AC cuboid of the same depth in beam direction are concatenated and flattened into 1D input sequences, and the LSTM model, which consists of a one-layer LSTM network and a two-layer fully-connected network (labeled as LSTM and FC), processes these combined sequences and outputs the predicted dose. (b) The corresponding LSTM module structure: x_t is the 1D flattened input slice received at each step, while h_t represents the corresponding 1D output sequence passed to the fully-connected network. The cell states c_{t-1} and c_t (previous and current steps) and the hidden states h_{t-1} and h_t (previous and current steps) are for maintaining the LSTM's memory. The σ functions denote the input, forget, and output gates of the LSTM, whereas the tanh functions denote the updating of the cell state information. Adapted from ref. [42].

function $\mathcal{L}$ of Model 1, 2, and 3 consisted of a standard MSE loss with an additional loss term to focus on the dose in the ACs.

$$\mathcal{L} = \text{MSE}(\mathbf{D}, \hat{\mathbf{D}}) + \lambda \cdot \text{MSE}(\mathbf{AC} \odot \mathbf{D}, \mathbf{AC} \odot \hat{\mathbf{D}}) \quad (1)$$

where $\mathbf{D}$ is the MC dose cuboid matrix, $\hat{\mathbf{D}}$ is the predicted dose cuboid matrix, $\mathbf{AC}$ is the AC cuboid matrix, $\odot$ represents element-wise multiplication (Hadamard product), and λ is the weighting factor (where factors of 1, 10, and 20 were explored, with 10 found to be optimal based on validation results and used).

All Unet models used the binary cross-entropy (BCE) loss, consistent with the AC segmentation study.⁴³ The Adam optimizer was employed to minimize the corresponding loss functions of our models. The learning rate was set to 10^{-5} and the batch size to 4. Models were implemented based on Python 3.11.9 and Pytorch 1.13.0 with an NVIDIA RTX A6000 GPU (48 GB memory) and the training time of each model was within two days. Models with the lowest validation loss were evaluated on the test dataset.

2.6 | Evaluation

After obtaining photon beam dose predictions from the four models, the 3D global gamma passing rates (γ_{pr} with a 2%/2 mm criteria and a threshold of 10% of the maximum dose D_{max}) between the predicted dose and MC dose were evaluated per cuboid using the open-source library PyMedphys.⁴⁴ The Wilcoxon signed-rank test was applied to γ_{pr} to assess statistically significant differences between the models. Additionally, for each dose cuboid, a dose mask was generated using a 15% D_{max} threshold to determine whether the dose passed through the ACs. The average γ_{pr} was then calculated for the cuboids where the dose intersected the ACs.

The Dice similarity coefficients (DSCs) between the manually contoured ACs and the Unet-based AC auto-segmentation on MRI were evaluated, where a threshold of 0.4, selected based on the highest validation DSC among thresholds ranging from 0.3 to 0.7 in increments of 0.1, was applied to the predicted AC to generate the binary mask. To quantify the size of ACs, we used 3D connected component analysis with 18-connectivity—where a voxel is connected to 6 face-sharing and 12 edge-sharing neighbors—on both manual and Unet-based masks to compute individual volumes, and further compared them before and after applying a 1 cc threshold, which reflects a more clinically practical override strategy.

For the single beam dose, the central axis dose profiles in beam direction (z-axis) and the lateral dose profiles (x-axis) in 30% and 80% of the maximum dose with corresponding relative dose differences ϵ_{rel} (%)

TABLE 1 Comparison of γ_{pr} and DSC values across four models in the test dataset.

Model	γ_{pr} (total)	γ_{pr} (dose through AC)	DSC
	mean $\pm$ SD (min)	mean $\pm$ SD (min)	mean $\pm$ SD
Model 0	99.96 $\pm$ 0.22 (93.30)	99.94 $\pm$ 0.25 (93.30)	\
Model 1	99.69 $\pm$ 0.77 (90.37)	99.68 $\pm$ 0.81 (94.42)	\
Model 2	99.68 $\pm$ 0.87 (91.93)	99.66 $\pm$ 0.91 (94.45)	0.62 $\pm$ 0.20
Model 3	99.53 $\pm$ 0.78 (89.63)	99.39 $\pm$ 1.10 (89.63)	0.60 $\pm$ 0.21

Abbreviations: AC, air cavities; DSC, dice similarity coefficient; SD, standard deviation.

were evaluated.

$$\epsilon_{\text{rel}} = 200 \frac{(D_{\text{pred}} - D_{\text{MC}})}{(D_{\text{pred}} + D_{\text{MC}})} [\%] \quad (2)$$

where D_{pred} and D_{MC} are the predicted and MC dose values through the central axis or lateral dose profiles.

To compare the full plan dose distributions obtained from the MC simulation and model predictions, we evaluated the 3D global gamma passing rate γ_{pr} (2%/2 mm, $D > 10\% D_{\text{max}}$), along with the dose volume histogram (DVH) and DVH indices for typical structures, including PTV ($D_{2\%}$, $D_{95\%}$), bladder ($D_{2\%}$, $V_{60\text{Gy}}$ and $V_{65\text{Gy}}$) and rectum ($D_{2\%}$, $V_{50\text{Gy}}$, $V_{60\text{Gy}}$, $V_{65\text{Gy}}$).

The model prediction runtime includes the cuboid extraction time and the model inference time (LSTM and Unet). All computation measurements were carried out on a workstation equipped with an Intel(R) Xeon(R) Gold 6354 3.00 GHz CPU and an NVIDIA RTX A6000 GPU.

3 | RESULTS

3.1 | Beam dose prediction results of Models 0, 1, 2, and 3

To evaluate the overall performance of the four models, the patient specific boxplots of γ_{pr} of predicted doses in the test dataset are shown in Figure 4. Although the MRI input-based models (Models 1, 2, 3) have slightly worse performances than the CT input-based model (Model 0), Models 1, 2, 3 can still achieve γ_{pr} 95th percentiles above 95%. Model 2 (using a separately trained Unet to predict AC) performed comparably to Model 1 (using ground truth AC). Table 1 presents the mean and worst γ_{pr} values of predicted doses from the four models, along with the mean DSC metrics of predicted ACs from the Unet of models 2 and 3 in the test dataset. The mean γ_{pr} of all models in the test dataset was higher than 99.5% and the mean DSC of the AC segmentation above 0.6. Table 2 presents the mean, standard deviation (SD), and range of AC volumes for both manual contours and Unet predictions




FIGURE 4 Patient specific boxplots for γ_{pr} of predicted dose cuboids from Models 0, 1, 2, and 3 in the test dataset. The red cross denotes the mean and the green line denotes the median value. The boxes denote the range between 25th and 75th percentiles. The orange whiskers denote the 5th and 95th percentiles, while the black points denote outliers outside of that range.

TABLE 2 The mean, SD, and range of the volume of ACs in the test dataset.

Dataset	Filtering	Mean $\pm$ SD (cm ³)	Range (cm ³)
Manual AC	None	0.25 $\pm$ 1.37	0.01–21.42
Manual AC	≥ 1 cm ³	5.47 $\pm$ 4.89	1.00–21.42
Unet AC	None	0.64 $\pm$ 2.71	0.01–44.65
Unet AC	≥ 1 cm ³	6.69 $\pm$ 6.96	1.00–44.65

Abbreviations: AC, air cavities; SD, standard deviation.

in the test dataset. On average, each test patient had 125 manually contoured ACs, which was reduced to 5 after applying the 1 cc volume threshold. The mean DSC after filtering was 0.65. In addition, γ_{pr} comparisons using the Wilcoxon signed-rank test ($p < 0.01$) revealed statistically significant differences between Model 0 (CT to dose) and Model 1 (MR with manual AC to dose), Model 1 and Model 2 (MR with Unet-predicted AC to dose, trained separately), as well as Model 2 and Model 3 (MR with Unet-predicted AC to dose, trained jointly).

Since Model 2 had γ_{pr} which were similar or better than Model 3, we selected Model 2 for the subsequent analysis. Model 1 was not considered due to the impossibility of manually delineating AC in real-time. For better visualization, beam dose prediction example cases were cropped to focus on the main dose region. Figure 5 presents a nominal case of dose propagation through AC, as predicted by Model 2 on the test dataset. The AC is automatically contoured from the MRI cuboid,

achieving a DSC of 0.76. Subsequently, the LSTM model predicts the dose distribution with a γ_{pr} passing rate of 100%. The central axis depth dose profile and two lateral dose profiles (at 30% and 80% of the maximum dose) for the predicted and MC dose matched well. Additionally, Model 2 accurately captured the dose fall-off within the AC. Figure 6 presents a nominal case where the dose does not pass through an AC, as predicted by Model 2 on the test dataset. The central axis depth dose profiles of predicted and MC dose exhibited strong agreement, with relative dose differences ϵ_{rel} smaller than 5% and a γ_{pr} of 99.98%. The two lateral dose profiles also demonstrated good consistency. Figure 7 shows the worst predicted case among the 10 test patients, which corresponds to a case where the dose does not pass through an AC. The central axis depth and two lateral dose profiles indicate that the predicted dose is lower than the MC dose, with a corresponding γ_{pr} of 91.93%.

Due to the ERE, we also presented a single-beam dose prediction example, highlighting the model's performance in the low-dose region, as shown in Figure 8. The colorbars for the MC and predicted dose were normalized to $2\%D_{max}$ of the MC dose as the upper limit and the prediction accuracy was assessed using the gamma passing rate γ_{pr} (2%/2 mm, $D > 0.5\%D_{max}$). From the dose distribution and the laterally accumulated dose profile comparison at the surface area, Model 2 exhibited limitations in accurately predicting the ERE near the patient surface.




FIGURE 5 A nominal case predicted by Model 2 (dose through AC, from P001 in Figure 4): yz slices of normalized (a) MC and (b) predicted dose, (c) manual and predicted AC on MRI, (d) the central axis depth dose profiles of normalized MC and predicted dose, (e) Γ (2%/2 mm) map of central dose plane, and (f) the lateral dose profiles of normalized MC and predicted dose with the relative dose differences. The central depth dose profile is through the gray dashed line and the positions of the two lateral dose profiles are indicated by two black arrows in the central axis dose profile.




FIGURE 6 A nominal case predicted by Model 2 (dose not through AC, from P004 in Figure 4): yz slices of normalized (a) MC and (b) predicted dose, (c) manual and predicted AC on MRI, (d) the central axis depth dose profiles of normalized MC and predicted dose, (e) Γ (2%/2 mm) map of central dose plane, and (f) the lateral dose profiles of normalized MC and predicted dose with the relative dose differences. The central depth dose profile is through the gray dashed line and the positions of the two lateral dose profiles are indicated by two black arrows in the central axis dose profile.




FIGURE 7 The worst case predicted by Model 2 (from P003 in Figure 4): yz slices of normalized (a) MC and (b) predicted dose, (c) manual and predicted AC on MRI, (d) the central axis depth dose profiles of normalized MC and predicted dose, (e) Γ (2%/2 mm) map of central dose plane, and (f) the lateral dose profiles of normalized MC and predicted dose with the relative dose differences. The central depth dose profile is through the gray dashed line and the positions of the two lateral dose profiles are indicated by two black arrows in the central axis dose profile.




FIGURE 8 A nominal case predicted by Model 2 highlighting the low-dose region: yz slices of normalized (a) MC and (b) predicted dose, (c) Γ (2%/2 mm) map of central dose plane on MRI, (d) the normalized laterally accumulated dose profiles of MC dose and predicted dose with the relative differences.

3.2 | Dose prediction results of five plans using Model 2

Figures 9 and 10 show the comparison of the plan dose distributions predicted from Model 2 and MC simulations for plans 1 (from P002) and 2 (from P006, with an AC near the PTV on MRI), respectively, with the comparisons for plans 3–5 provided in Figures S1–S3. The γ_{pr} values of the two plans were 99.99% and 99.93%

respectively. The DVH curves for the predicted and MC doses from two cases are close to each other in the low and high dose levels for the evaluated PTV and organ-at-risk structures. Table 3 presents the corresponding DVH indices for the five test plans, with the largest observed differences being less than 1.0 Gy and 1.2%. Table 4 shows the γ_{pr} comparison of five full plans with 2%/2 mm, 1%/2 mm, 1%/1 mm criteria with the threshold of $D > 10\%D_{max}$.




FIGURE 9 Transverse slice of the (a) predicted dose, (b) MC dose, both with the 30, 50, and 70 Gy isodose lines, (c) γ (2%/2 mm) map with the corresponding γ index histogram, and (d) DVH (predicted dose solid line and MC dose as dashed line) for Plan 1 (from P002). MC, Monte Carlo; DVH, dose volume histogram.




FIGURE 10 Transverse slice of the (a) predicted dose, (b) MC dose, both with the 30, 50, and 70 Gy isodose lines, (c) γ (2%/2 mm) map with the corresponding γ index histogram, and (d) DVH (predicted dose solid line and MC dose as dashed line) for Plan 2 (from P006). An AC is visible in the rectal area under the PTV on the MRI. MC, Monte Carlo; DVH, dose volume histogram; PTV, planning training volume.

TABLE 3 DVH indices and differences (prediction-MC) of five plan dose distributions from Model 2 and MC simulation. Prescription dose 74 Gy.

		PTV		Bladder			Rectum			
		D _{2%} (Gy)	D _{95%} (Gy)	D _{2%} (Gy)	V _{60Gy} (%)	V _{65Gy} (%)	D _{2%} (Gy)	V _{50Gy} (%)	V _{60Gy} (%)	V _{65Gy} (%)
Plan 1 (P002)	Model 2	77.3	70.0	71.2	11.0	8.2	72.4	28.7	13.3	9.1
	MC	77.3	70.4	72.1	12.1	8.5	72.8	28.7	13.6	9.4
	Difference	0.0	-0.4	-0.9	-1.1	-0.3	-0.4	0.0	-0.3	-0.3
Plan 2 (P006)	Model 2	77.4	70.2	74.1	9.0	6.9	74.1	32.0	15.8	11.4
	MC	77.4	70.4	74.0	8.9	6.9	73.9	32.0	16.0	11.6
	Difference	0.0	-0.2	0.1	0.1	0.0	0.2	0.0	-0.2	-0.2
Plan 3 (P005)	Model 2	77.0	69.9	71.9	10.0	7.5	70.7	12.9	8.4	5.6
	MC	77.5	70.4	72.1	10.1	7.9	71.2	12.9	8.8	6.0
	Difference	-0.5	-0.5	-0.2	-0.1	-0.4	-0.5	0.0	-0.4	-0.4
Plan 4 (P008)	Model 2	79.0	70.2	75.8	13.6	10.9	70.2	13.8	8.1	5.2
	MC	78.9	70.4	76.0	13.9	11.4	70.0	13.8	8.1	5.0
	Difference	-0.1	-0.2	-0.2	-0.3	-0.5	0.2	0.0	0.0	0.2
Plan 5 (P009)	Model 2	78.3	70.3	76.1	25.4	20.6	71.7	17.0	11.2	7.8
	MC	78.6	70.4	75.9	25.4	20.7	71.8	17.0	11.3	8.0
	Difference	-0.3	-0.1	0.2	0.0	-0.1	-0.1	0.0	-0.1	-0.2

Abbreviations: DVH, dose volume histogram; MC, Monte Carlo; PTV, planning training volume.

TABLE 4 γ_{pr} comparison of five full plans with 2%/2mm, 1%/2mm, and 1%/1mm criteria in the $D > 10\%D_{max}$ region.

Plan	γ_{pr} (2%/2mm) value (%)	γ_{pr} (1%/2mm) value (%)	γ_{pr} (1%/1mm) value (%)
Plan 1 (P002)	99.99	99.67	98.81
Plan 2 (P006)	99.93	99.49	97.97
Plan 3 (P005)	99.89	99.17	97.38
Plan 4 (P008)	99.80	99.36	97.91
Plan 5 (P009)	99.96	99.71	98.56

3.3 | Model prediction runtimes

The average extraction time for an MRI cuboid was about 43 ms, and the averaged inference time of the LSTM and Unet model for a single photon dose cuboid was around 7 and 5 ms, respectively. In total, the prediction time of Model 2 was around 60 ms, with a GPU memory requirement of less than 2 GB for inference.

4 | DISCUSSION

In this study, we introduced a DL-based synthetic-CT-free photon dose calculation method, integrating LSTM and Unet networks. In these initial results, focusing on prostate radiotherapy under a 0.35 T magnetic field, we demonstrated that our approach effectively models the mapping between MRI and photon beam dose distribu-

tions simulated on the corrected deformed CT. Although using MRI as model input results in a slight reduction in accuracy compared to the model that directly uses CT (as shown in Figure 4), our MRI-based model (Model 2) can still achieve a mean gamma passing rate γ_{pr} (2%/2 mm, $D > 10\%D_{max}$) higher than 99.5% in the single-beam test. Besides, both the DVH analysis and gamma passing rate γ_{pr} (2%/2 mm, $D > 10\%D_{max}$) demonstrated high agreement in the full-plan evaluation, suggesting the feasibility of performing DL dose calculations directly on MRI. In contrast to previously published DL-based dose calculation methods that rely on CT-based input, end-to-end dose calculation on MRI can bypass the time-consuming process of generating 3D synthetic CT. Additionally, the proposed framework can consider AC variations near the prostate region in real-time.

Model 3, trained with a joint multi-task loss, performed slightly worse than the two single-task sub-models (Model 2). The heterogeneous objectives, using BCE for voxel-wise binary classification and MSE for regression, might have caused loss-scale imbalance that impeded joint optimization. Given that the separately trained sub-models of Model 2 already demonstrated satisfactory performance, we did not further pursue more complex multi-task strategies in this study. For the worst predicted beam dose case from Model 2, we have two potential hypotheses for the reduced prediction accuracy: First, the subtle spatial misalignment between the input MR and the ground-truth corrected CT at the beam entrance region may have contributed to the error, as shown in the Figure S4. Due to the dose values outside the body mask

derived from the MRI being set to zero, such misalignment in high-dose-gradient regions may lead to dose over- or underestimation and affect subsequent dose propagation. Second, we cannot exclude the possibility that residual errors from the deformable registration process may introduce spatial mismatches that degraded prediction accuracy. Using a fused CT/MR body contour or a water equivalent correction for the corrected CT may be a more robust approach for such cases. In addition, although our LSTM model exhibited limitations in accurately predicting the ERE near the patient surface, for multi-field plans (Figures 9 and 10) on low-field (0.35 T) MR-Linacs, the cumulative dose contributions from multiple beam angles inherently attenuate localized dose enhancements caused by ERE. An additional loss function targeting surface dose regions and more advanced neural network architectures will be explored to address this issue in future studies.

Clinically, MRI is affected by low-frequency intensity inhomogeneity changes, commonly known as bias field artifacts.⁴⁵ These artifacts result from various factors related to image acquisition, including coil positioning, coil sensitivities, magnetic field inhomogeneities, and patient-related factors. Correcting these low-frequency artifacts may help improve our DL model's performance. To assess the impact of bias field artifacts, we applied the N4 bias field correction algorithm using the same parameters as those used in another DL segmentation study⁴⁶ on our 0.35 T MRI and compared the results with the uncorrected MRI using Model 2. Consistent with the findings in that study,⁴⁶ we observed that bias field correction did not enhance the DL dose prediction outputs. Our DL model is robust to the variations caused by bias field artifacts, suggesting that DL dose calculation on MRI can be performed accurately without the need for bias field corrections.

The MR scanner used in this study has a magnetic field strength of 0.35 T and employs the bSSFP sequence, with MC dose simulation also conducted under an idealized 0.35 T magnetic field and using a generic 6 MV photon source. It may be worthwhile to explore DL dose calculation using 1.5 T MRI and under the 1.5 T magnetic field from an Elekta Unity MR-Linac.² While the improved MRI image resolution and signal-to-noise ratio from a stronger magnetic field might enhance DL dose calculation accuracy, the associated stronger magnetic dose effects might also complicate DL dose modeling. In addition, specialized MR sequences, such as Cartesian 3D FLASH or 3D TFE,⁴³ could be utilized to further enhance the accuracy of DL-based AC segmentation in the abdominopelvic region. Our models achieved an average DSC of approximately 0.6, which improved to around 0.65 after filtering out small AC contour region with the volume less than 1 cc, suggesting potential for further improvement with a more suitable MRI sequence as demonstrated in another study.⁴³ Besides, instead of performing AC segmenta-

tion across the entire patient anatomy, we opted to apply AC segmentation within a cuboid region that specifically targets areas relevant to dose calculation, thereby improving computational efficiency.

Although the dosimetric impact of ACs is often considered negligible in multi-beam or arc therapy due to dose averaging and scattering of large field beams for prostate patients, a rectum IMRT study has shown that air pockets near or within the target volume can introduce non-negligible local dose perturbations under the magnetic field.⁴⁷ Moreover, air pockets may vary in shape and position during and between fractions, introducing residual uncertainties.⁴⁸ For the dose effect of the ACs, small fields present a clearer observation of the dose reduction in the air cavity, where the phenomenon can be masked by the re-establishment of charged particle equilibrium from larger fields. For these initial proof-of-concept results, we simulated all the photon beams with a uniform $1 \times 1 \text{ cm}^2$ field size and optimized five nine-field plans for testing. This configuration can not only generate arbitrary fluence maps using optimized weights, but also enables a clearer evaluation of local dose deviations and supports the development of segmentation-based correction strategies. The network was only specifically trained for prostate treatment sites. The ultimate goal of DL photon dose calculation on MRI is to accurately compute dose distributions across multiple treatment sites with varying multileaf collimator (MLC) shapes. As the current framework lacks dedicated modeling for MLC MC simulation, incorporating MLC information into the DL model will be part of the next stage. MLC segment BEV projection methods, similar to those used in CT-based DL dose calculation,^{22,23} could be applied in our future studies.

This study focused and is therefore limited to prostate cases. For more complex anatomical structures outside the prostate region, such as the abdomen and lungs, further exploration remains both essential and challenging. In the abdominal region, the motion of organs such as the intestines, stomach, liver, and kidneys due to respiration and peristalsis poses greater challenges for deformable CT-MRI registration. Furthermore, the presence of larger and more dynamic ACs within multiple gas-containing organs, including the intestines, stomach, duodenum, and rectum, further increases the complexity of AC corrections compared to prostate. In the lung region, CT-MRI pair data exhibit significant discrepancies due to the inherently low MR signal in lung tissue (resulting from low proton density), the presence of small structures such as the bronchi, and MRI distortions, including susceptibility and motion artifacts. Additionally, manual AC corrections in the lung are often impractical, particularly in the bronchial areas. Synthetic CT generation from MRI also encounters similar challenges in lung cases, as indicated by the mean γ_{pr} ($2\%/2 \text{ mm}$, $D > 10\%D_{max}$) values, which ranged approximately 95%–96% for lung plan cases, compared to over

98% for abdominal and pelvic plan cases.⁴⁹ Accurately obtaining paired CT-MRI data labels is crucial, and the development of integrated CT-MRI scanners⁵⁰ may offer a promising solution to these challenges.

Inspired by the SynthRAD2023 Grand Challenge,^{14,15} organizing a synthetic-CT-free dose calculation challenge, incorporating paired CT-MRI data, plan information and corresponding time-consuming MC dose labels from multiple sites, presents a compelling direction for future research. Instead of calculating dose on DL-based synthetic CTs, a more direct comparison between dose predictions from MRI and MC dose from labeled CT could be achieved. End-to-end MRI-based dose calculation would also enable intra-fractional plan adaptation based on 3D time-resolved MRI in the context of real-time motion management.⁸ Finally, although our current DL models, based on simple LSTM and Unet architectures, have demonstrated promising performance in prostate cases, organizing such challenges to compare the performance of different DL models and training strategies, such as Unet-based methods^{22,24–27} and LSTM/transformer-based methods under BEV,^{23,29,30} would be valuable. Such a competition could provide valuable insights into the clinical applications of DL-based dose calculation.

5 | CONCLUSION

We proposed a DL-based dose calculation framework that acts directly on MRI and demonstrated its feasibility in this proof-of-concept study for prostate cases. This approach has the potential to simplify procedures for MRI-only workflows and could be beneficial for real-time plan adaptation by omitting synthetic CT generation.

ACKNOWLEDGMENTS

The work of Fan Xiao was supported by the China Scholarship Council (No.202308440107), and this project was supported by Deutsche Forschungsgemeinschaft (No.469106425). The authors also acknowledge Mr. Ahmad Neishabouri for his insightful discussions on this work.

Open access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST STATEMENT

The Department of Radiation Oncology of the LMU University Hospital Munich has research agreements with Brainlab, Elekta and ViewRay.

DATA AVAILABILITY STATEMENT

The data cannot be made publicly available upon publication because they contain sensitive personal information. The data that support the findings of this study are available upon reasonable request from the authors.

REFERENCES

- Schmidt MA, Payne GS. Radiotherapy planning using MRI. *Phys Med Biol*. 2015;60:R323.
- Lagendijk JJ, Raaijmakers BW, Van Vulpen M. The magnetic resonance imaging–linac system. *Semin Radiat Oncol*. 2014;24:207–209.
- Klueter S. Technical design and concept of a 0.35 T MR-linac. *Clinical and translational radiation oncology*. 2019;18:98–101.
- Winkel D, Bol GH, Kroon PS, et al. Adaptive radiotherapy: the Elekta Unity MR-linac concept. *Clinical and translational radiation oncology*. 2019;18:54–59.
- Kurz C, Buizza G, Landry G, et al. Medical physics challenges in clinical MR-guided radiotherapy. *Radiat Oncol*. 2020;15:1–16.
- Green OL, Rankine LJ, Cai B, et al. First clinical implementation of real-time, real anatomy tracking and radiation beam control. *Med Phys*. 2018;45:3728–3740.
- Keall PJ, Brighi C, Glide-Hurst C, et al. Integrated MRI-guided radiotherapy—opportunities and challenges. *Nat Rev Clin Oncol*. 2022;19:458–470.
- Lombardo E, Dhont J, Page D, et al. Real-time motion management in MRI-guided radiotherapy: Current status and AI-enabled prospects. *Radiother Oncol*. 2024;190:109970.
- Paganelli C, Portoso S, Garau N, et al. Time-resolved volumetric MRI in MRI-guided radiotherapy: an in silico comparative analysis. *Phys Med Biol*. 2019;64:185013.
- Wu C, Murray V, Siddiq SS, et al. Real-time 4D MRI using MR signature matching (MRSIGMA) on a 1.5 T MR-Linac system. *Phys Med Biol*. 2023;68:185015.
- Kontaxis C, Bol G, Lagendijk J, Raaijmakers B. A new methodology for inter-and intrafraction plan adaptation for the MR-linac. *Phys Med Biol*. 2015;60:7485.
- Kontaxis C, Bol G, Stemkens B, et al. Towards fast online intrafraction replanning for free-breathing stereotactic body radiation therapy with the MR-linac. *Phys Med Biol*. 2017;62:7233.
- Bahloul MA, Jabeen S, Benoumhani S, Alsaleh HA, Belkhatir Z, Al-Wabil A. Advancements in synthetic CT generation from MRI: A review of techniques, and trends in radiation therapy planning. *J Appl Clin Med Phys*. 2024;25:e14499.
- Thummerer A, Bijl E, Galapon Jr A, et al. SynthRAD2023 Grand Challenge dataset: Generating synthetic CT for radiotherapy. *Med Phys*. 2023;50:4664–4674.
- Huijben EM, Terpstra ML, Pai S, et al. Generating synthetic computed tomography for radiotherapy: SynthRAD2023 challenge report. *Med Image Anal*. 2024;97:103276.
- Vellini L, Quaranta F, Menna S, et al. A deep learning algorithm to generate synthetic computed tomography images for brain treatments from 0.35 T magnetic resonance imaging. *Phys Imaging Radiat Oncol*. 2025;33:100708.
- Vestergaard CD, Vatterodt N, Elstrøm UV, et al. Comparing methods to improve cone-beam computed tomography for dose calculations in adaptive proton therapy. *Phys Imaging Radiat Oncol*. 2025:100784.
- Raaijmakers AJ, Raaijmakers BW, Lagendijk JJ. Magnetic-field-induced dose effects in MR-guided radiotherapy systems: dependence on the magnetic field strength. *Phys Med Biol*. 2008;53:909.
- Khan AU, Simiele EA, Lotey R, DeWerd LA, Yadav P. Development and evaluation of a GEANT4-based Monte Carlo Model of a 0.35 T MR-guided radiation therapy (MRgRT) linear accelerator. *Med Phys*. 2021;48:1967–1982.
- Li Y, Ding S, Wang B, Liu H, Huang X, Song T. Extension and validation of a GPU-Monte Carlo dose engine gDPM for 1.5 T MR-LINAC online independent dose verification. *Med Phys*. 2021;48:6174–6183.
- Cheng B, Xu Y, Li S, et al. Development and clinical application of a GPU-based Monte Carlo dose verification module and software for 1.5 T MR-LINAC. *Med Phys*. 2023;50:3172–3183.

22. Xiao F, Cai J, Zhou X, Zhou L, Song T, Li Y. TransDose: a transformer-based UNet model for fast and accurate dose calculation for MR-LINACs. *Phys Med Biol*. 2022;67:125013.
23. Pastor-Serrano O, Dong P, Huang C, Xing L, Perkó Z. Sub-second photon dose prediction via transformer neural networks. *Med Phys*. 2023;50:3159-3171.
24. Kontaxis C, Bol G, Lagendijk J, Raaymakers B. DeepDose: Towards a fast dose calculation engine for radiation therapy using deep learning. *Phys Med Biol*. 2020;65:075013.
25. Tsekas G, Bol GH, Raaymakers BW, Kontaxis C. DeepDose: a robust deep learning-based dose engine for abdominal tumours in a 1.5 T MRI radiotherapy system. *Phys Med Biol*. 2021;66:065017.
26. Fan J, Xing L, Dong P, Wang J, Hu W, Yang Y. Data-driven dose calculation algorithm based on deep U-Net. *Phys Med Biol*. 2020;65:245035.
27. Schneider M, Gutwein S, Mönnich D, et al. Development and comprehensive clinical validation of a deep neural network for radiation dose modelling to enhance magnetic resonance imaging guided radiotherapy. *Phys Imaging Radiat Oncol*. 2025:100723.
28. Rabe M, Paganelli C, Riboldi M, et al. Porcine lung phantom-based validation of estimated 4D-MRI using orthogonal cine imaging for low-field MR-Linacs. *Phys Med Biol*. 2021;66:055006.
29. Neishabouri A, Wahl N, Mairani A, Köthe U, Bangert M. Long short-term memory networks for proton dose calculation in highly heterogeneous tissues. *Med Phys*. 2021;48:1893-1908.
30. Radonic D, Xiao F, Wahl N, et al. Proton dose calculation with LSTM networks in presence of a magnetic field. *Phys Med Biol*. 2024;69:215019.
31. Bieri O, Scheffler K. Fundamentals of balanced steady state free precession MRI. *J Magn Reson Imaging*. 2013;38:2-11.
32. Acharya S, Fischer-Valuck BW, Kashani R, et al. Online magnetic resonance image guided adaptive radiation therapy: first clinical applications. *Int J Radiat Oncol Biol Phys*. 2016;94:394-403.
33. Bohoudi O, Bruynzeel AM, Senan S, et al. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. *Radiother Oncol*. 2017;125:439-444.
34. Thapa R, Ahunbay E, Nasief H, Chen X, Li XA. Automated air region delineation on MRI for synthetic CT creation. *Phys Med Biol*. 2020;65:025009.
35. Wasserthal J, Breit HC, Meyer MT, et al. TotalSegmentator: robust segmentation of 104 anatomic structures in CT images. *Radiol Artif Intell*. 2023;5(5):e230024.
36. Lemus OMD, Tanny S, Cummings M, et al. Influence of air mapping errors on the dosimetric accuracy of prostate CBCT-guided online adaptive radiation therapy. *J Appl Clin Med Phys*. 2023;24:e14057.
37. Schmid S, Landry G, Thieke C, et al. Monte Carlo study on the sensitivity of prompt gamma imaging to proton range variations due to interfractional changes in prostate cancer patients. *Phys Med Biol*. 2015;60:9329.
38. Capote R, Jeraj R, Ma C, et al. Phase-space database for external beam radiotherapy. Summary report of a consultants' meeting. *International Atomic Energy Agency*. Austria. 2006.
39. Wahl N, Becher T, Bucher L, Leininger F, Ortkamp T, Stanic G. pyRadPlan. *Zenodo*. 2025; 15006910.
40. Wieser HP, Cisternas E, Wahl N, et al. Development of the open-source dose calculation and optimization toolkit matRad. *Med Phys*. 2017;44:2556-2568.
41. Abbani N, Al-Hasnawi N, Ackermann B, et al. matRad. *Zenodo*. 2024; 14181851.
42. Xiao F, Radonic D, Kriechbaum M, et al. Prompt gamma emission prediction using a long short-term memory network. *Phys Med Biol*. 2024;69:235003.
43. Ahunbay E, Parchur AK, Xu J, Thill D, Paulson ES, Li XA. Automated deep learning auto-segmentation of air volumes for MRI-guided online adaptive radiation therapy of abdominal tumors. *Phys Med Biol*. 2023;68:125011.
44. Biggs S, Jennings M, Swerdloff S, et al. PyMedPhys: A community effort to develop an open, Python-based standard library for medical physics applications. *J Open Source Software*. 2022;7:4555.
45. Vovk U, Pernus F, Likar B. A review of methods for correction of intensity inhomogeneity in MRI. *IEEE Trans Med Imaging*. 2007;26:405-421.
46. Vagni M, Tran HE, Catucci F, et al. Impact of bias field correction on 0.35 T pelvic MR images: evaluation on generative adversarial network-based OARs' auto-segmentation and visual grading assessment. *Front Oncol*. 2024;14: 1294252.
47. Uilkema S, Heide U, Sonke JJ, Moreau M, Triest B, Nijkamp J. A 1.5 T transverse magnetic field in radiotherapy of rectal cancer: Impact on the dose distribution. *Med Phys*. 2015;42:7182-7189.
48. Bol G, Lagendijk J, Raaymakers B. Compensating for the impact of non-stationary spherical air cavities on IMRT dose delivery in transverse magnetic fields. *Phys Med Biol*. 2015;60: 755.
49. Lenkowicz J, Votta C, Nardini M, et al. A deep learning approach to generate synthetic CT in low field MR-guided radiotherapy for lung cases. *Radiother Oncol*. 2022;176:31-38.
50. Peng Y, Li M, Grandinetti J, Wang G, Jia X. Top-level design and simulated performance of the first portable CT-MR scanner. *IEEE Access*. 2022;10:102325-102333.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Xiao F, Radonic D, Wahl N, et al. Deep learning-based synthetic-CT-free photon dose calculation in MR-guided radiotherapy: A proof-of-concept study. *Med Phys*. 2025;52:e70106. <https://doi.org/10.1002/mp.70106>